Evidence map›Paper›PMID 42883686›Full record

ArticleInternational journal of molecular sciences2026

Plasma Lipids Associated with Endothelial Dysfunction in Patients with Type 2 Diabetes: A Cross-Sectional Study Using Lipidomic Analysis.

Naohiro Taya, Naoto Katakami, Kazuo Omori, Shigero Hosoe, Mitsuyoshi Takahara, Kazuyuki Miyashita, Shugo Sasaki, Yutaka Konya, Sachiko Obara, Ayako Hidaka and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Naohiro TayaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
Naoto KatakamiDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0001-9020-8320
Kazuo OmoriDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
Shigero HosoeDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
Mitsuyoshi TakaharaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0001-5105-041X
Kazuyuki MiyashitaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
Shugo SasakiDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.ORCID 0000-0002-3696-7809
Yutaka KonyaDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.
Sachiko ObaraDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.
Ayako HidakaDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.
Motonao NakaoDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.
Masatomo TakahashiDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.
Yoshihiro IzumiDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.ORCID 0000-0003-4608-4652
Takeshi BambaDivision of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Fukuoka, Japan.
Iichiro ShimomuraDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, 2-2, Yamadaoka, Suita 565-0871, Osaka, Japan.

Funding

Japan Agency for Medical Research and Development JP19gm0710005Japan Agency for Medical Research and Development JP21gm0910013Japan Agency for Medical Research and Development JP21gm1010010Japan Diabetes FoundationJapan Society for the Promotion of Science 25K11804Kyushu University JPMXP1323015486Manpei Suzuki Diabetes Foundation
6 · The paper itself

Abstract

Patients with diabetes often develop abnormalities in lipid metabolism that can promote diabetic complications. Lipidomic studies have demonstrated that certain plasma lipid species are associated with the development of cardiovascular diseases. However, the plasma lipids associated with endothelial dysfunction remain unclear. To identify the lipids associated with flow-mediated vasodilation (FMD), an indicator of endothelial function, in patients with diabetes, we performed a cross-sectional analysis as a subanalysis of a previous lipidomic study. In total, 200 patients with type 2 diabetes were included in the analysis. A total of 55.0% were men, and the mean age (±standard deviation) was 61.1 ± 11.3 years. Their HbA1c and FMD values were 9.04 ± 1.79% (75.3 ± 19.5 mmol/mol) and 5.77 ± 2.55%, respectively. Supercritical fluid chromatography/mass spectrometry-based semi-targeted lipidomic analysis identified 349 lipids belonging to 16 lipid classes. We selected 13 distinctive lipids potentially associated with FMD, according to a sparse-group least absolute shrinkage and selection operator regularized regression model. Of these, seven phospholipids, including three phosphatidylethanolamine (PE) plasmalogens and three phosphatidylinositols (PIs), showed a positive association with FMD after adjusting for atherosclerotic risk factors. These findings may contribute to improving the assessment and management of endothelial dysfunction in patients with diabetes.

Indexed as

Diabetes Mellitus, Type 2Endothelium, VascularLipidomicsLipidsAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedVasodilationLipidsdiabetic complicationendothelial dysfunctionflow-mediated vasodilationlipidomicsphospholipidstype 2 diabetes

Identifiers

PMID42883686
PMCPMC13665545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.